GTG Genetic Technologies

Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report

Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report

MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

In the exclusive interview, Dr. Muchnicki discusses the Company’s innovative disease risk assessment tests for COVID-19, cancer, and more.

To view the interview segment, please visit:

“The RedChip Money Report" delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

About Genetic Technologies Limited

Genetic Technologies Limited is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit  

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements,” within the meaning of federal securities laws, including statements related to the Company’s anticipated use of proceeds and plans and prospects and other statements containing the words “anticipate,” “intend,” “may,” “plan,” “predict,” “will,” “would,” “could,” “should,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company’s prior filings and from time to time in the Company’s subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

FOR FURTHER INFORMATION PLEASE CONTACT

Investor Relations and Media (US)

Dave Gentry, CEO

RedChip Companies

Office: 1 800 RED CHIP (733 2447)

Cell: US 407 491 4498



EN
23/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genetic Technologies

 PRESS RELEASE

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2 MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomics-based...

 PRESS RELEASE

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Pla...

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification ...

 PRESS RELEASE

Genetic Technologies Announces Global Launch of geneType™ on Wholly Ow...

Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company’s current A$7.5m annual revenues....

 PRESS RELEASE

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15 MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of genomic...

 PRESS RELEASE

Genetic Technologies Strategic Restructure Driving USA Sales Growth

Genetic Technologies Strategic Restructure Driving USA Sales Growth CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch